Vox Sanguinis最新文献

Evaluation of the progress of a decade-long haemovigilance programme in India. 对印度长达十年之久的血液警戒计划进展情况的评估。

IF 1.8 4区医学

Vox Sanguinis Pub Date : 2024-10-06 DOI: 10.1111/vox.13741

Akanksha Bisht, Gopal Kumar Patidar, Satyam Arora, Neelam Marwaha

{"title":"Evaluation of the progress of a decade-long haemovigilance programme in India.","authors":"Akanksha Bisht, Gopal Kumar Patidar, Satyam Arora, Neelam Marwaha","doi":"10.1111/vox.13741","DOIUrl":"https://doi.org/10.1111/vox.13741","url":null,"abstract":"Background and objectives: Implementation of national haemovigilance programmes has significantly improved donor and recipient safety. Recently, India completed a decade of successful implementation of its national haemovigilance programmes. The national programme is still enrolling more blood centres. This study aimed to highlight the strengths and weaknesses of Haemovigilance Programme of India (HvPI), thereby providing valuable insights for future initiatives.Materials and methods: The National Coordinating Centre (NCC) conducted a multi-centre, cross-sectional questionnaire-based survey among the reporting blood centres (January to April 2022). The survey consisted of three sections with a total of 27 questions focusing on the demographics of the participant blood centre as well as the impact on the recipient and donor haemovigilance. The survey was sent to 733 blood centres regularly reporting to the donor and recipient HvPI through Donor and Hemovigil Software.Results: Total 296 responses were received (response rate of 40.4%) with maximum participation of private non-teaching hospital-based blood centres (33.8%). After their involvement in recipient HvPI, 85.7% of the respondents reported changes in their blood centre's work procedures, with the maximum improvement seen in the documentation of transfusion reactions (92.7%). Out of the 278 respondents who participated in donor HvPI, 89.9% (250) found that their blood centre's policies or work process changed as a result of their involvement in the programme.Conclusion: In conclusion, our haemovigilance programme facilitates national collaboration for learning and sharing experiences, leading to improved policies and practices in reducing adverse reactions for both recipients and donors.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142381753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-neutralizing antibody profiles against hepatitis B virus: A comparative study of Japanese- and US-donor-derived intramuscular human hepatitis B-specific immunoglobulin preparations. 针对乙型肝炎病毒的非中和抗体概况：源自日本和美国的肌肉注射人乙型肝炎特异性免疫球蛋白制剂的比较研究。

IF 1.8 4区医学

Vox Sanguinis Pub Date : 2024-10-02 DOI: 10.1111/vox.13742

Tatsuki Miyamoto, Hiroko Okamoto, Shoya Hori, Kei Sato, Katsushi Murai

引用次数: 0

Frequency of human platelet antigens (HPA) in the Greek population as deduced from the first registry of HPA-typed blood donors. 从首个 HPA 型献血者登记处推断出的希腊人口中人类血小板抗原 (HPA) 的频率。

IF 1.8 4区医学

Vox Sanguinis Pub Date : 2024-09-23 DOI: 10.1111/vox.13739

Georgios Kaltsounis, Evangelia Boulomiti, Dimitroula Papadopoulou, Dimitrios Stoimenis, Fotios Girtovitis, Eleni Hasapopoulou-Matamis

{"title":"Frequency of human platelet antigens (HPA) in the Greek population as deduced from the first registry of HPA-typed blood donors.","authors":"Georgios Kaltsounis, Evangelia Boulomiti, Dimitroula Papadopoulou, Dimitrios Stoimenis, Fotios Girtovitis, Eleni Hasapopoulou-Matamis","doi":"10.1111/vox.13739","DOIUrl":"https://doi.org/10.1111/vox.13739","url":null,"abstract":"Background and objectives: Human platelet antigens (HPA) play a central role in foetal and neonatal alloimmune thrombocytopenia (FNAIT), post-transfusion purpura and some cases of platelet therapy refractoriness. The frequency distribution of HPA had not been studied in the Greek population before we started to create a registry of HPA-typed apheresis platelet donors. The aim of this study was the determination of the frequency of various HPA in the Greek population, through the establishment of a registry of typed donors.Materials and methods: Here, we report on the first 1000 platelet donors of Greek origin who gave informed consent and were genotyped for 12 pairs of antithetical HPA by Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), including HPA-1, HPA-3, HPA-5 and HPA-15. Antigen frequencies are reported, and allele frequencies were calculated and compared with other European and non-European populations. Tested donors cover all ABO and Rhesus D antigen spectrum.Results: Antigen and allele frequencies are very similar to other White populations. The frequency of HPA-1bb is 2.9% in our study, and the frequency of HPA-2b, HPA-4b, HPA-9b and HPA-15b is also slightly higher than in other literature reports, while the frequency of HPA-15b was found higher than that of HPA-15a.Conclusion: We report antigen and allele frequencies for a large array of clinically significant HPA for the first time in the Greek population. Frequencies are consistent with other European populations. This registry of HPA-typed platelet donors, available to donate on demand, is an important asset for the treatment of FNAIT cases in Greece.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142308635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regular whole blood donation and gastrointestinal, breast, colorectal and haematological cancer risk among blood donors in Australia. 澳大利亚献血者定期捐献全血与患胃肠道癌、乳腺癌、结肠直肠癌和血癌的风险。

IF 1.8 4区医学

Vox Sanguinis Pub Date : 2024-09-19 DOI: 10.1111/vox.13734

Md Morshadur Rahman, Andrew Hayen, John K Olynyk, Anne E Cust, David O Irving, Surendra Karki

{"title":"Regular whole blood donation and gastrointestinal, breast, colorectal and haematological cancer risk among blood donors in Australia.","authors":"Md Morshadur Rahman, Andrew Hayen, John K Olynyk, Anne E Cust, David O Irving, Surendra Karki","doi":"10.1111/vox.13734","DOIUrl":"https://doi.org/10.1111/vox.13734","url":null,"abstract":"Background and objectives: Several studies have suggested that blood donors have lower risk of gastrointestinal and breast cancers, whereas some have indicated an increased risk of haematological cancers. We examined these associations by appropriately adjusting the 'healthy donor effect' (HDE).Materials and methods: We examined the risk of gastrointestinal/colorectal, breast and haematological cancers in regular high-frequency whole blood (WB) donors using the Sax Institute's 45 and Up Study data linked with blood donation and other health-related data. We calculated 5-year cancer risks, risk differences and risk ratios. To mitigate HDE, we used 5-year qualification period to select the exposure groups, and applied statistical adjustments using inverse probability weighting, along with other advanced doubly robust g-methods.Results: We identified 2867 (42.4%) as regular high-frequency and 3888 (57.6%) as low-frequency donors. The inverse probability weighted 5-year risk difference between high and low-frequency donors for gastrointestinal/colorectal cancer was 0.2% (95% CI, -0.1% to 0.5%) with a risk ratio of 1.25 (0.83-1.68). For breast cancer, the risk difference was -0.2% (-0.9% to 0.4%), with a risk ratio of 0.87 (0.48-1.26). Regarding haematological cancers, the risk difference was 0.0% (-0.3% to 0.5%) with a risk ratio of 0.97 (0.55-1.40). Our doubly robust estimators targeted minimum loss-based estimator (TMLE) and sequentially doubly robust (SDR) estimator, yielded similar results, but none of the findings were statistically significant.Conclusion: After applying methods to mitigate the HDE, we did not find any statistically significant differences in the risk of gastrointestinal/colorectal, breast and haematological cancers between regular high-frequency and low-frequency WB donors.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoantibodies to ADAMTS13 in human immunodeficiency virus‐associated thrombotic thrombocytopenic purpura 人类免疫缺陷病毒相关血栓性血小板减少性紫癜中的 ADAMTS13 自身抗体

IF 2.7 4区医学

Vox Sanguinis Pub Date : 2024-09-19 DOI: 10.1111/vox.13738

Muriel Meiring, Mmakgabu Khemisi, Susan Louw, Palanisamy Krishnan

{"title":"Autoantibodies to ADAMTS13 in human immunodeficiency virus‐associated thrombotic thrombocytopenic purpura","authors":"Muriel Meiring, Mmakgabu Khemisi, Susan Louw, Palanisamy Krishnan","doi":"10.1111/vox.13738","DOIUrl":"https://doi.org/10.1111/vox.13738","url":null,"abstract":"Background and ObjectivesThrombotic thrombocytopenic purpura (TTP) is a potentially fatal thrombotic microangiopathic disorder that can result from human immunodeficiency virus (HIV) infection. The pathogenesis involves a deficiency of the von Willebrand factor (vWF) cleaving protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin motifs member 13) and the presence of anti‐ADAMTS13 autoantibodies. However, there is insufficient information regarding the epitope specificity and reactivity of these autoantibodies. This study aimed to perform epitope‐mapping analysis to provide novel insights into the specific epitopes on ADAMTS13 domains affected by autoantibodies.Materials and MethodsThe study analysed 59 frozen citrate plasma samples from HIV‐associated TTP patients in South Africa, measuring ADAMTS13 activity using Technozyme® ADAMTS13 activity test, total immunoglobulin (Ig) M and IgA antibodies levels using ELISA kit and purifying IgG antibodies using NAb™ Protein G spin columns. A synthetic ADAMTS13 peptide library was used for epitope mapping.ResultsOverall, 90% of samples showed anti‐ADAMTS13 IgG autoantibodies, with 64% of these antibodies being inhibitory, as revealed by mixing studies. Samples with ADAMTS13 antigen levels below 5% showed high anti‐ADAMTS13 IgG autoantibody titres (≥50 IU/mL), whereas those with 5%–10% levels had low autoantibody titres (<50 IU/mL).The metalloprotease, cysteine‐rich and spacer domains were 100% involved in binding anti‐ADAMTS13 IgG antibodies, with 58% of samples containing antibodies binding to the C‐terminal part of the ADAMTS13 disintegrin‐like domain, indicating different pathogenic mechanisms.ConclusionThe metalloprotease, cysteine‐rich and spacer domains are the primary targets for anti‐ADAMTS13 IgG autoantibodies in patients with HIV‐associated TTP. These findings suggest potential effects on the proteolytic activity of ADAMTS13, highlighting the complex nature of the pathogenic mechanisms involved.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142249877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extending the post‐thaw shelf‐life of cryoprecipitate when stored at refrigerated temperatures 在冷藏条件下储存低温沉淀可延长其解冻后的保质期

IF 2.7 4区医学

Vox Sanguinis Pub Date : 2024-09-19 DOI: 10.1111/vox.13736

Kelly M. Winter, Rachel G. Webb, Eugenia Mazur, Peta M. Dennington, Denese C. Marks

{"title":"Extending the post‐thaw shelf‐life of cryoprecipitate when stored at refrigerated temperatures","authors":"Kelly M. Winter, Rachel G. Webb, Eugenia Mazur, Peta M. Dennington, Denese C. Marks","doi":"10.1111/vox.13736","DOIUrl":"https://doi.org/10.1111/vox.13736","url":null,"abstract":"Background and ObjectivesThe post‐thaw shelf‐life of cryoprecipitate is 6 h, leading to high wastage. Storage of thawed cryoprecipitate at refrigerated temperatures may be feasible to extend the shelf‐life. This study aimed to evaluate the quality of thawed cryoprecipitate stored at 1–6°C for up to 14 days.Materials and MethodsCryoprecipitate (mini‐ and full‐size packs derived from both apheresis and whole blood [WB] collections) was thawed, immediately sampled and then stored at 1–6°C for up to 14 days. Mini‐packs were sampled at 6, 24, 48 and 72 h, day 7 and 14; full‐size cryoprecipitate was sampled on day 3, 5 or 7. Coagulation factors (F) II, V, VIII, IX, X and XIII, von Willebrand factor (VWF) and fibrinogen were measured using a coagulation analyser. Thrombin generation was measured by calibrated automated thrombogram.ResultsFVIII decreased during post‐thaw storage; this was significant after 24 h for WB (p = 0.0002) and apheresis (p < 0.0001). All apheresis and eight of 20 WB cryoprecipitate met the FVIII specification (≥ 70 IU/unit) on day 14 post‐thaw. Fibrinogen remained stable for 48 h, and components met the specification on day 14 post‐thaw. There were no significant differences in VWF (WB p = 0.1292; apheresis p = 0.1507) throughout storage. There were small but significant decreases in thrombin generation lag time, endogenous thrombin potential and time to peak for both WB and apheresis cryoprecipitate.ConclusionWhilst coagulation factors in cryoprecipitate decreased after post‐thaw storage, the thawed cryoprecipitate met the Council of Europe specifications when stored at refrigerated temperatures for 7 days.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142249878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to ‘Determining the impact of current Canadian stem cell registry policy on donor availability via dynamic registry simulation’ 通过动态登记模拟确定加拿大干细胞登记处现行政策对捐献者可用性的影响 "的更正

IF 2.7 4区医学

Vox Sanguinis Pub Date : 2024-09-15 DOI: 10.1111/vox.13737

引用次数: 0

The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa 南非输血患者中乙型肝炎病毒、人类 T 淋巴细胞病毒和人体免疫缺陷病毒的流行情况

IF 2.7 4区医学

Vox Sanguinis Pub Date : 2024-09-11 DOI: 10.1111/vox.13735

Reynier J. Willemse, Christa J. Grobler, Edward L. Murphy, Nareg Roubinian, Charl Colemen, Solly Machaba, Marion Vermeulen

{"title":"The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa","authors":"Reynier J. Willemse, Christa J. Grobler, Edward L. Murphy, Nareg Roubinian, Charl Colemen, Solly Machaba, Marion Vermeulen","doi":"10.1111/vox.13735","DOIUrl":"https://doi.org/10.1111/vox.13735","url":null,"abstract":"Background and ObjectivesSouth Africa has a high prevalence of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and to a lesser extent human T‐lymphotropic virus (HTLV). Each of these agents is transfusion‐transmissible (TT) but deciding whether to implement preventive screening depends upon knowledge of background prevalence in transfused patients. We determined the prevalence of HIV, HBV and HTLV I/II among blood transfusion recipients in South African hospitals.Materials and MethodsWe obtained identity‐unlinked samples used for blood cross‐matching at 634 South African hospitals served by the South African National Blood Service (SANBS). The ABBOTT Alinity S® Immunochemiluminescent system measured HIV, HBV and HTLV I/II antibodies. Repeatedly reactive samples were confirmed using the Roche Cobas® 8000. Logistic regression was performed to investigate the determinants of associations for HIV, HBV and HTLV infections.ResultsThe overall prevalences of HIV, HBV and HTLV were 37.8%, 7.4% and 0.6%, respectively. The HIV prevalence in blood recipients was twice as high as general population estimates. Public hospital patients had a significantly higher prevalence compared with private hospital patients for HIV and HBV. HIV prevalence was significantly higher in females, and HBV prevalence was significantly higher in males, excluding the unknown gender results.ConclusionPatients receiving blood transfusions in South Africa have high rates of HIV and HBV infection that should be taken into consideration when determining donor screening strategies for other viral infections. Measurable prevalence of HTLV indicates endemicity of this infection in South Africa.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142219772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Events 活动

IF 2.7 4区医学

Vox Sanguinis Pub Date : 2024-09-11 DOI: 10.1111/vox.13733

引用次数: 0

A comprehensive approach to continuous quality improvement of massive transfusion by developing key performance indicators 通过制定关键绩效指标持续改进大规模输血质量的综合方法

IF 2.7 4区医学

Vox Sanguinis Pub Date : 2024-09-10 DOI: 10.1111/vox.13732

Ancy Ninan, Vimal Krishnan, Shamee Shastry, Ganesh Mohan, Deepika Chenna, Deep Madkaiker, Jayaraj Mymbilly Balakrishnan

{"title":"A comprehensive approach to continuous quality improvement of massive transfusion by developing key performance indicators","authors":"Ancy Ninan, Vimal Krishnan, Shamee Shastry, Ganesh Mohan, Deepika Chenna, Deep Madkaiker, Jayaraj Mymbilly Balakrishnan","doi":"10.1111/vox.13732","DOIUrl":"https://doi.org/10.1111/vox.13732","url":null,"abstract":"Background and ObjectivesTo develop key performance indicators (KPI) for use in quality assessment of our institutional goal‐directed massive transfusion (GDMT).Materials and MethodsA team comprising our transfusion and emergency medicine departments carried out a cross‐sectional data analysis of GDMT in adult patients from January 2021 to December 2022. The study was rooted in the Define, Measure, Analyse, Improve, Control (DMAIC) approach. Features of KPIs were (a) importance, (b) scientific soundness and (c) feasibility. Study parameters were defined and analysed using measures of central tendencies and benchmark comparison.ResultsNinety‐two massive transfusion events occurred and 1405 blood components were used. Trauma was the leading cause, followed by postpartum haemorrhage and upper gastrointestinal bleeding. Appropriate GDMT activation was observed only in 43.47% of events. The turnaround time (TAT) was within the benchmark in 85.8% of events with an average of 16 ± 10 min. The average utilization of blood components was 20.5 (interquartile range [IQR] = 11.3) in the appropriate group and 5.5 (IQR = 4.25) in the inappropriate group with a wastage rate of 3.5%. Duration of activation was 6.19 ± 4.59 h, and the adherence to thromboelastography was 66.3%. Overall mortality was 45.65%, and the average duration of hospital stay was 6.1 ± 5.9 days.ConclusionThe KPIs developed were easy to capture, and the analysis provided a comprehensive approach to the quality improvement of the GDMT protocol.","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142219683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0